Piotr Podwalski

Dr. Piotr Podwalski

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
PMPiotr Marcinowicz
Piotr Marcinowicz
MWMagdalena Więdłocha
Magdalena Więdłocha
NZNatalia Zborowska
Natalia Zborowska
WDWeronika Dębowska
Weronika Dębowska
PPPiotr Podwalski
Piotr Podwalski
ASAgata Szulc
Agata Szulc
Background: Cytokines have a major impact on the neurotransmitter networks that are involved in schizophrenia pathophysiology. First Episode Psychosis (FEP) patients exhibit abnormalities in cytokines levels prior to the start of treatment. Previous studies showed that antipsychotic treatment modulates cytokines levels. The aim of this meta-analysis is to further investigate this relationship. Methods: Several online databases were searched. For meta-analysis of selected studies, we analysed variables containing the number of cases, mean and standard deviation of IL-1β, IL-2, IL-4, IL-6, IL-10, IL-17, TNF-α, IFN-γ levels before, and after, antipsychotic treatment. Results: 12 studies were included in the meta-analysis. Our main results demonstrate that, in FEP patients, antipsychotic treatment is related to decreased concentrations of pro-inflammatory IL-1β, IL-6, IFN-γ, TNF-α and anti-inflammatory IL-4, IL-10 cytokines. On the other hand, levels of pro-inflammatory IL-2 and IL-17 remain unaffected. Conclusions: When compared with other meta-analyses of studies involving FEP individuals, results we obtained are consistent regarding decrease in IL-1β, IL-6. Comparing outcomes of our study with meta-analyses of schizophrenic subjects, in general, our results are consistent in IL-1β, IL-6, TNF-α, IFN-γ, IL-2. Our meta-analysis is the only one which indicates a decrease in anti-inflammatory IL-10 in FEP patients after antipsychotic treatment.

27 August 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
BDBartosz Dawidowski
Bartosz Dawidowski
AGAdrianna Górniak
Adrianna Górniak
PPPiotr Podwalski
Piotr Podwalski
ZLZofia Lebiecka
Zofia Lebiecka
Blazej MisiakBlazej Misiak
Blazej Misiak
JSJerzy Sanochowiec
Jerzy Sanochowiec
Schizophrenia is a chronic mental illness of unknown etiology. A growing and compelling body of evidence implicates immunologic dysfunction as the key element in its pathomechanism. Cytokines, whose altered levels have been increasingly reported in various patient populations, are the major mediators involved in the coordination of the immune system. The available literature reports both elevated levels of proinflammatory as well as reduced levels of anti-inflammatory cytokines, and their effects on clinical status and neuroimaging changes. There is evidence of at least a partial genetic basis for the association between cytokine alterations and schizophrenia. Two other factors implicated in its development include early childhood trauma and disturbances in the gut microbiome. Moreover, its various subtypes, characterized by individual symptom severity and course, such as deficit schizophrenia, seem to differ in terms of changes in peripheral cytokine levels. While the use of a systematic review methodology could be difficult due to the breadth and diversity of the issues covered in this review, the applied narrative approach allows for a more holistic presentation. The aim of this narrative review was to present up-to-date evidence on cytokine dysregulation in schizophrenia, its effect on the psychopathological presentation, and links with antipsychotic medication. We also attempted to summarize its postulated underpinnings, including early childhood trauma and gut microbiome disturbances, and propose trait and state markers of schizophrenia.

30 October 2020 in Pharmacological Reports
Verified
Journal Article
Open access
PDF file
PPPiotr Podwalski
Piotr Podwalski
KSKrzysztof Szczygieł
Krzysztof Szczygieł
ETErnest Tyburski
Ernest Tyburski
LSLeszek Michał Sagan
Leszek Michał Sagan
Blazej MisiakBlazej Misiak
Blazej Misiak
JSJerzy Sanochowiec
Jerzy Sanochowiec
Diffusion tensor imaging (DTI) is an imaging technique that uses magnetic resonance. It measures the diffusion of water molecules in tissues, which can occur either without restriction (i.e., in an isotropic manner) or limited by some obstacles, such as cell membranes (i.e., in an anisotropic manner). Diffusion is most often measured in terms of, inter alia, fractional anisotropy (FA), mean diffusivity (MD), radial diffusivity (RD), and axial diffusivity (AD). DTI allows us to reconstruct, visualize, and evaluate certain qualities of white matter. To date, many studies have sought to associate various changes in the distribution of diffusion within the brain with mental diseases and disorders. A better understanding of white matter integrity disorders can help us recognize the causes of diseases, as well as help create objective methods of psychiatric diagnosis, identify biomarkers of mental illness, and improve pharmacotherapy. The aim of this work is to present the characteristics of DTI as well as current research on its use in schizophrenia, affective disorders, and other mental disorders.

1 October 2018 in Psychoneuroendocrinology
Verified
Journal Article
Closed access
Blazej MisiakBlazej Misiak
Blazej Misiak
KKKamila Kotowicz
Kamila Kotowicz
OLOlga Loska
Olga Loska
FSFilip Stramecki
Filip Stramecki
JBJan Aleksander Beszłej
Jan Aleksander Beszłej
PPPatryk Piotrowski
Patryk Piotrowski

Verified
Journal Article
Open access
PDF file
KRKatarzyna Rek-Owodziń
Katarzyna Rek-Owodziń
ETErnest Tyburski
Ernest Tyburski
PPPiotr Plichta
Piotr Plichta
KWKatarzyna Waszczuk
Katarzyna Waszczuk
MBMaksymilian Bielecki
Maksymilian Bielecki
MMMonika Mak
Monika Mak
Impairments in cognitive functions are one of the main features of schizophrenia. A variety of factors can influence the extent of cognitive deficits. In our study, we examined the severity of cognitive deficits at different stages of the disease and the relationship between psychopathological symptoms and cognitive functions. We recruited 32 patients with first-episode psychosis (FEP), 70 with chronic schizophrenia (CS), and 39 healthy controls (HC). Psychopathological symptoms were evaluated with the Positive and Negative Syndrome Scale (PANSS) and cognitive functions were measured with the MATRICS Cognitive Consensus Battery (MCCB). Cognitive deficits were present in both FEP and CS participants. CS individuals had lower overall scores and poorer working memory; however, clinical variables appeared to play a significant role in these scores. In FEP, disorganization correlated negatively with verbal and visual learning and memory, social cognition, and overall score; negative symptoms negatively correlated with social cognition. In CS participants, disorganization correlated negatively with speed of processing, reasoning, problem solving, and overall score; negative symptoms were negatively correlated with speed of processing, visual learning, memory, and overall score; positive symptoms were negatively correlated with reasoning and problem solving. Our findings indicate that psychopathological symptoms have a significant impact on cognitive functions in FEP and CS patients.

31 December 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
BDBartosz Dawidowski
Bartosz Dawidowski
GGGrzegorz Grelecki
Grzegorz Grelecki
ABAdam Biłgorajski
Adam Biłgorajski
PPPiotr Podwalski
Piotr Podwalski
Blazej MisiakBlazej Misiak
Blazej Misiak
JSJerzy Sanochowiec
Jerzy Sanochowiec
Background: Studies have shown that there are deviations in the results of peripheral blood counts, which lead to increased values of the neutrophils-to-lymphocytes ratio (NLR) in schizophrenia. Antipsychotic drugs have proven to lower the levels of pro-inflammatory cytokines and a growing number of studies indicate a similar effect on NLR values. Methods: We identified inpatients with schizophrenia and collected data of NLR at the beginning (NLR1) and end (NLR2) of hospitalization, the status of antipsychotic medication on admission and potential confounding factors. In the statistical analysis, we applied a linear mixed model. Results: After the inclusion and exclusion process the records of 40 patients (np = 40) and 71 hospitalizations (nh = 71) were analyzed. We found that in the group of antipsychotics-naive patients, the NLR1 were significantly higher than the NLR2 values. Such a difference did not occur in the case of non-antipsychotics-naïve patients. Age and the diagnosis of hypothyroidism influenced the value of change in NLR from the beginning to the end of hospitalization in a given patient (ΔNLR). Conclusions: The study confirmed the lowering effect of antipsychotics on NLR values in psychosis. The NLR may potentially be a tool for assessing response to treatment with antipsychotics.